A detailed history of Black Rock Inc. transactions in Scynexis Inc stock. As of the latest transaction made, Black Rock Inc. holds 423,738 shares of SCYX stock, worth $533,909. This represents 0.0% of its overall portfolio holdings.

Number of Shares
423,738
Previous 341,733 24.0%
Holding current value
$533,909
Previous $502,000 68.73%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.4 - $2.77 $114,806 - $227,153
82,005 Added 24.0%
423,738 $847,000
Q1 2024

May 10, 2024

SELL
$1.39 - $2.21 $128,359 - $204,082
-92,345 Reduced 21.27%
341,733 $502,000
Q4 2023

Feb 13, 2024

BUY
$1.56 - $2.24 $4,945 - $7,100
3,170 Added 0.74%
434,078 $967,000
Q3 2023

Nov 13, 2023

BUY
$1.93 - $3.64 $3,348 - $6,315
1,735 Added 0.4%
430,908 $982,000
Q2 2023

Aug 11, 2023

BUY
$2.38 - $3.67 $117,286 - $180,857
49,280 Added 12.97%
429,173 $1.27 Million
Q1 2023

May 12, 2023

SELL
$1.15 - $3.0 $45,548 - $118,821
-39,607 Reduced 9.44%
379,893 $1.14 Million
Q4 2022

Feb 13, 2023

BUY
$1.46 - $2.94 $2,560 - $5,156
1,754 Added 0.42%
419,500 $654,000
Q3 2022

Nov 14, 2022

SELL
$1.83 - $2.93 $411 - $659
-225 Reduced 0.05%
417,746 $1 Million
Q2 2022

Aug 12, 2022

BUY
$1.77 - $3.87 $76,163 - $166,526
43,030 Added 11.48%
417,971 $778,000
Q1 2022

May 12, 2022

SELL
$3.56 - $6.66 $1,085 - $2,031
-305 Reduced 0.08%
374,941 $1.47 Million
Q4 2021

Feb 10, 2022

BUY
$4.94 - $7.69 $250,868 - $390,521
50,783 Added 15.65%
375,246 $2.29 Million
Q3 2021

Nov 09, 2021

SELL
$5.3 - $7.89 $21,173 - $31,520
-3,995 Reduced 1.22%
324,463 $1.72 Million
Q2 2021

Aug 11, 2021

BUY
$6.5 - $9.97 $2.13 Million - $3.27 Million
328,458 New
328,458 $2.42 Million

Others Institutions Holding SCYX

About SCYNEXIS INC


  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $41.1M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.